Profile Response Detail

Molecular Profile ERBB2 negative
Therapy Docetaxel + Ramucirumab
Indication/Tumor Type Her2-receptor negative breast cancer
Response Type no benefit
Create By stafford
Update By tyin

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 negative Her2-receptor negative breast cancer no benefit Docetaxel + Ramucirumab Phase III Actionable In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099). 25185099
PubMed Id Reference Title Details
(25185099) Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. Full reference...